Literature DB >> 6350256

Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins.

P M Shah, W Stille.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6350256     DOI： 10.1093/jac/11.6.597

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  20 in total

1.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

2.  Epidemiology of extended spectrum beta-lactamases.

Authors:  A Philippon; S Ben Redjeb; G Fournier; A Ben Hassen
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

3.  E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.

Authors:  Mariagrazia Perilli; Giuseppe Celenza; Francesca De Santis; Cristina Pellegrini; Chiara Forcella; Gian Maria Rossolini; Stefania Stefani; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

4.  Detection of SHV-5 extended-spectrum beta-lactamase in Klebsiella pneumoniae strains isolated in Italy.

Authors:  A Marchese; G Arlet; G C Schito; P H Lagrange; A Philippon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

5.  In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

Authors:  A Bauernfeind; S Schweighart; E Eberlein; R Jungwirth
Journal:  Infection       Date:  1991       Impact factor: 3.553

6.  Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals.

Authors:  P Legrand; G Fournier; A Buré; V Jarlier; M H Nicolas; D Decré; J Duval; A Philippon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

7.  Novel plasmid-mediated beta-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins.

Authors:  A Petit; D L Sirot; C M Chanal; J L Sirot; R Labia; G Gerbaud; R A Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

8.  Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility.

Authors:  G Mendelson; V Hait; J Ben-Israel; D Gronich; E Granot; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

9.  Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins.

Authors:  A Bauernfeind; G Hörl
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

10.  Spread of Klebsiella pneumoniae producing SHV-5 beta-lactamase among hospitalized patients.

Authors:  A Bauernfeind; E Rosenthal; E Eberlein; M Holley; S Schweighart
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.